History | Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma | Guidance | NICE

History

Documents created during the development process.

Expected publication

Equality Impact Assessment (Guidance development) (PDF 145 KB)

Published:

24 February 2021
Register of interests (PDF 123 KB)

Published:

24 February 2021

Final draft guidance

Final draft guidance
Final appraisal document (PDF 230 KB)

Published:

19 January 2021
Final appraisal document - managed access agreement (PDF 380 KB)

Published:

19 January 2021
Committee papers (PDF 6.89 MB)

Published:

19 January 2021
Public committee slides (PDF 1.55 MB)

Published:

19 January 2021

Invitation to participate

Final stakeholder list (PDF 216 KB)

Published:

13 February 2020
Final scope (PDF 179 KB)

Published:

13 February 2020
NICE's response to comments on the draft scope and provisional stakeholder list (PDF 281 KB)

Published:

13 February 2020
Equality impact assessment (Scoping) (PDF 124 KB)

Published:

15 December 2020

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

Draft scope post referral (PDF 209 KB)

Published:

25 October 2019
Draft matrix post referral (PDF 207 KB)

Published:

25 October 2019

Notes

Note
Note